“Growing Use of Interleukin-6 (IL-6) Inhibitors”
The bare metal stents (BMS) market continues to expand, driven by the increasing prevalence of coronary artery disease (CAD) and the ongoing need for cost-effective treatments. One key trend in the market is the growing adoption of BMS in emerging markets due to their affordability and effectiveness in treating CAD. While drug-eluting stents (DES) have become the gold standard in many developed countries, BMS remains a preferred option in regions such as Asia-Pacific and Africa, where healthcare budgets are more constrained. For instance, in India and parts of Southeast Asia, BMS is widely used because of its lower cost compared to DES, while still offering improved outcomes over balloon angioplasty. As healthcare access improves in these regions, the demand for BMS is expected to rise. In addition, advancements in stent materials, such as the use of cobalt-chromium alloys, are enhancing stent performance, reducing restenosis rates, and improving patient outcomes, further bolstering market growth.
